- Home
- GSUN vs XBIO Comparison
GSUN vs XBIO Comparison
Compare GSUN & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSUN
- XBIO
- Stock Information
- Founded
- GSUN 1997
- XBIO N/A
- Country
- GSUN China
- XBIO United States
- Employees
- GSUN N/A
- XBIO N/A
- Industry
- GSUN Other Consumer Services
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GSUN Real Estate
- XBIO Health Care
- Exchange
- GSUN Nasdaq
- XBIO Nasdaq
- Market Cap
- GSUN N/A
- XBIO 5.8M
- IPO Year
- GSUN 2022
- XBIO N/A
- Fundamental
- Price
- GSUN $2.87
- XBIO $2.67
- Analyst Decision
- GSUN
- XBIO Hold
- Analyst Count
- GSUN 0
- XBIO 1
- Target Price
- GSUN N/A
- XBIO N/A
- AVG Volume (30 Days)
- GSUN 15.4K
- XBIO 6.9K
- Earning Date
- GSUN 04-08-2025
- XBIO 03-18-2025
- Dividend Yield
- GSUN N/A
- XBIO N/A
- EPS Growth
- GSUN N/A
- XBIO N/A
- EPS
- GSUN N/A
- XBIO N/A
- Revenue
- GSUN $10,159,020.00
- XBIO $2,500,284.00
- Revenue This Year
- GSUN N/A
- XBIO N/A
- Revenue Next Year
- GSUN N/A
- XBIO $27.78
- P/E Ratio
- GSUN N/A
- XBIO N/A
- Revenue Growth
- GSUN 65.04
- XBIO N/A
- 52 Week Low
- GSUN $2.21
- XBIO $2.26
- 52 Week High
- GSUN $9.93
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- GSUN 46.24
- XBIO 27.60
- Support Level
- GSUN $2.80
- XBIO $3.25
- Resistance Level
- GSUN $3.25
- XBIO $3.43
- Average True Range (ATR)
- GSUN 0.21
- XBIO 0.24
- MACD
- GSUN -0.02
- XBIO -0.08
- Stochastic Oscillator
- GSUN 24.00
- XBIO 25.63
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.